Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.
Alexey G MittenbergValeria O KuzykSergey V ShabelnikovDaria P GorbachAlla N ShatrovaOlga A FedorovaNickolai A BarlevPublished in: Cell cycle (Georgetown, Tex.) (2018)
BD: bortezomib/doxorubicin treatment; CDK: cyclin-dependent kinases; CHCA: α-cyanohydroxycinnamic acid; IDP: intrinsically disordered proteins; IDR: intrinsically disordered regions; IPG: immobilized pI gradient; MALDI TOF/TOF: matrix-assisted laser desorption/ionization time-of-flight tandem mass-spectrometry; MM: multiple myeloma; ODC: ornithine decarboxylase; PI: proteasomal inhibitors; PSMA: alpha-type 20S proteasome subunits; PTMs: post-translational modifications; SDS-PAGE: sodium dodecylsulphate polyacrylamide gel electrophoresis; UIP: ubiquitin-independent proteasomal proteolysis.
Keyphrases
- multiple myeloma
- mass spectrometry
- tandem mass spectrometry
- high performance liquid chromatography
- endothelial cells
- cell cycle
- drug delivery
- induced apoptosis
- simultaneous determination
- high resolution
- cell proliferation
- oxidative stress
- smoking cessation
- induced pluripotent stem cells
- capillary electrophoresis
- pluripotent stem cells
- pet imaging